Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 601–700 of 1,000
Preformulation in Drug Research and Pharmaceutical Product Development
Acharya, P. C., Shetty, S. R., Fernandes, C., Suares, D., Maheshwari, R., & Tekade, R. K. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-814423-7.00001-0 · Cited by 26
Sandelius, Å., Basak, J., Hölttä, M., Sultana, S. R., Hyberg, G., Wilson, A., Andersson, P. U., & Söderberg, M. P. (2020) · Toxicologic Pathology · doi:10.1177/0192623320964391 · Cited by 16
“Drug-induced kidney injury (DIKI) is a significant contributor to drug attrition.(1) Traditional kidney safety biomarkers such as serum creatinine, blood urea nitrogen (BUN), urinalysis, urine albumin, and urine total protein have been used to monitor renal safety in both clinical and preclinical studies but have limi…”
BackgroundA high-throughput method for predicting drug effects on gut transit time using larval zebrafish
Cassar, S. C., Huang, X., & Cole, T. B. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.08.156 · Cited by 16
Multiomics integration prioritizes potential drug targets for multiple sclerosis
Jiang, Y., Liu, Q., Stridh, P., Kockum, I. S., Olsson, T. P., Alfredsson, L. S., Díaz-Gallo, L.-M., & Jiang, X. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2425537122 · Cited by 18
“GWAS: genome - wide association study.”
Body-on-a-Chip Systems for Animal-free Toxicity Testing
Mahler, G. J., Esch, M. B., Stokol, T., Hickman, J. J., & Shuler, M. L. (2016) · Alternatives to Laboratory Animals · doi:10.1177/026119291604400508 · Cited by 16
Burt, T., Roffel, A. F., Langer, O., Anderson, K., & DiMasi, J. A. (2022) · Clinical and Translational Science · doi:10.1111/cts.13269 · Cited by 16
Does Therapeutic Repurposing in Cancer Meet the Expectations of Having Drugs at a Lower Price?
González‐Fierro, A., Romo‐Pérez, A., Chávez-Blanco, A. D., Domínguez-Gómez, G., & Dueñas‐González, A. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01251-0 · Cited by 15
“The initial screening of compound libraries [70–72] leads to selecting a single compound, which only has an approximately 8% chance of succeeding in clinical trials [73].”
BackgroundPhaneuf, C. G., Aizikov, K., Grinfeld, D., Kreutzmann, A., Mourad, D., Lange, O., Dai, D., Zhang, B., Belenky, A., Makarov, A., et al. (2023) · Communications Chemistry · doi:10.1038/s42004-023-00861-1 · Cited by 17
Matsushita, K., Toyoda, T., Akane, H., Morikawa, T., & Ogawa, K. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4554 · Cited by 17
Umbricht, D., Kas, M. J., & Dawson, G. R. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.08.511 · Cited by 16
“The need to demonstrate target engagement cannot be stressed enough as a lack of clear target engagement may account for up to 30 % of all drug failures (Cook et al., 2014).”
BackgroundValencia, Z. S., Kingston, J. L. T., Miljković, F. N., Rowbottom, H., Mann, N., Davies, S., Ekblad, M., Castro, S. D., Kwapień, K., Malmerberg, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01642 · Cited by 17
Isobe, T., Honda, M., Komatsu, R., & Tabo, M. (2018) · The Journal of Toxicological Sciences · doi:10.2131/jts.43.493 · Cited by 19
Glineur, S., Hanon, É., Dremier, S., Snelling, S., Berteau, C., Ron, P. D., & da Costa, A. N. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy213 · Cited by 15
Xu, Y., & Li, Z. (2019) · Medicinal Research Reviews · doi:10.1002/med.21566 · Cited by 15
“A recent report from the pharmaceutical company AstraZeneca showed that high proportion (57% in phase IIa and 88% in phase IIb) of their late‐stage drug development project attrition is due to the failure to achieve sufficient efficacy, and nearly a quarter (21%) of the failed projects provide no proof of the target e…”
BackgroundResultOda, S., & Yokoi, T. (2021) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2020.11.007 · Cited by 15
Okeyo, P. O., Rajendran, S. T., Zór, K., & Boisen, A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113850 · Cited by 15
Pan, Z., Fan, J., & Eslam, M. (2021) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2021.07.007 · Cited by 19
Identifying multiscale translational safety biomarkers using a network-based systems approach
Callegaro, G., Schimming, J. P., Piñero, J., Kunnen, S. J., Wijaya, L. S., Trairatphisan, P., van den Berk, L., Beetsma, K., Furlong, L. I., Sutherland, J. J., et al. (2023) · iScience · doi:10.1016/j.isci.2023.106094 · Cited by 17
“The industry reports that unacceptable safety accounts for more than 50% of project closures, and that in particular failure to detect a safety signal in preclinical screens using in vitro, in vivo or in silico tools is responsible for 40% of safety attrition.(1)”
BackgroundTranslatability score revisited: differentiation for distinct disease areas
Wendler, A., & Wehling, M. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1329-y · Cited by 16
The cancer cell proteome and transcriptome predicts sensitivity to targeted and cytotoxic drugs
Rydenfelt, M., Wongchenko, M. J., Klinger, B., Yan, Y., & Blüthgen, N. (2019) · Life Science Alliance · doi:10.26508/lsa.201900445 · Cited by 17
“Pharmacogenomic studies have been instrumental to derive biomarkers (Barretina et al, 2012; Garnett et al, 2012; Cook et al, 2014; Costello et al, 2014; Klijn et al, 2014; Haverty et al, 2016; Iorio et al, 2016); yet, genomic biomarkers are largely limited to mutations that are directly targeted by…”
Slavin, I., Dea, S., Arunkumar, P., Sodhi, N., Montefusco, S., Siqueira-Neto, J. L., Seelke, J., Lofstrom, M. A., Anson, B. D., Zanella, F., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041908 · Cited by 16
“Central nervous system (CNS) toxicity is a major concern in drug development and a frequent cause of attrition in late-stage clinical trials as well as in the withdrawal of already approved drugs from the market [1].”
BackgroundIn vitro screening of cell bioenergetics to assess mitochondrial dysfunction in drug development
Tilmant, K., Gerets, H. H. J., Ron, P. D., Hanon, É., Bento‐Pereira, C., & Atienzar, F. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2018.07.012 · Cited by 18
Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer
Jäger, T., Ocker, M., Kiesslich, T., Neureiter, E., & Neureiter, D. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1274392 · Cited by 15
“technical success frombench to launch [14] (see also https://www.”
Background3D-printed, configurable, paper-based, and autonomous multi-organ-on-paper platforms
Li, H., Cheng, F., Wang, Z., Li, W., Robledo-Lara, J. A., & Zhang, Y. S. (2022) · Molecular Systems Design & Engineering · doi:10.1039/d2me00142j · Cited by 14
Bieske, L., Zinner, M., Dahlhausen, F., & Trübel, H. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103734 · Cited by 24
Non-Coding RNAs: Foes or Friends for Targeting Tumor Microenvironment
Szymanowska, A., Rodríguez-Aguayo, C., Lopez-Berestein, G., & Amero, P. (2023) · Non-Coding RNA · doi:10.3390/ncrna9050052 · Cited by 12
Targeting papain-like protease by natural products as novel therapeutic potential SARS-CoV-2
Waqas, M. S., Ullah, S. M., Halim, S. A., Rehman, N. U., Ali, A., Jan, A., Muhsinah, A. B., Khan, A., & Al‐Harrasi, A. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128812 · Cited by 14
Cata, J. P., & Sessler, D. I. (2024) · Anesthesiology · doi:10.1097/aln.0000000000004823 · Cited by 15
Biological Networks and Drug Discovery—Where Do We Stand?
Geppert, T., & Koeppen, H. (2014) · Drug Development Research · doi:10.1002/ddr.21207 · Cited by 16
“There are many publications that focus on possible reasons for the lack of productivity in pharmaceutical R&D, often with an emphasis on the organization, its decision-making processes, and the efficiency and budgeting of the research process [Kola and Landis, 2004; Williams, 2011; Forda et al., 2013; Ringel et al., 2…”
BackgroundPreclinical Characterization of the Phosphodiesterase 10A PET Tracer [11C]MK-8193
Hostetler, E. D., Fan, H. S., Joshi, A. D., Zeng, Z., Eng, W., Gantert, L. T., Holahan, M. A., Meng, X., Miller, P. J., O'Malley, S. S., et al. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0910-0 · Cited by 14
“Since binding of a drug to the target of interest is a prerequisite for affecting the desired pharmacology, the measurement of target engagement (TE) is a widely espoused biomarker strategy, and one that has been buoyed by the use of positron emission tomography (PET), in particular for neuroscience mechanisms where a…”
BackgroundIvanov, D. P., Al-Rubai, A.-J. F., Grabowska, A. M., & Pratten, M. K. (2016) · Toxicology in Vitro · doi:10.1016/j.tiv.2016.09.007 · Cited by 17
Ingelman-Sundberg, M., & Lauschke, V. M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0096 · Cited by 14
Fine mapping with epigenetic information and 3D structure
Orozco, G. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-021-00906-4 · Cited by 15
Piossek, F., Beneke, S., Schlichenmaier, N., Mucic, G., Drewitz, S., & Dietrich, D. R. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.109959 · Cited by 15
A Knowledge Graph-Enhanced Tensor Factorisation Model for Discovering Drug Targets
Ye, C., Swiers, R., Bonner, S., & Barrett, I. P. (2022) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2022.3197320 · Cited by 18
Selecting the right therapeutic target for kidney disease
Buvall, L., Menzies, R. I., Williams, J. H., Woollard, K. J., Kumar, C., Granqvist, A., Fritsch, M., Féliers, D., Reznichenko, A., Gianni, D., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.971065 · Cited by 17
“In addition, many studies have shown that when a target can be linked to genetic evidence in disease, or a firm understanding of the role of a target in the etiology of a disease, these are less likely to fail due to insufficient efficacy (Kamb et al., 2013; Plenge et al., 2013; Cook et al., 2014; Hurle et al., 2016;…”
BackgroundGuo, X., Wei, W., Liu, M., Cai, T., Wu, C., & Wang, J. (2022) · Journal of the American Statistical Association · doi:10.1080/01621459.2022.2157727 · Cited by 23
Quantitative Systems Pharmacology and Machine Learning: A Match Made in Heaven or Hell?
Tindall, M. J., Cucurull-Sanchez, L., Mistry, H. B., & Yates, J. W. T. (2023) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.122.001551 · Cited by 15
Communication in Drug Development: “Translating” Scientific Discovery
Settleman, J., & Cohen, R. L. (2016) · Cell · doi:10.1016/j.cell.2016.02.050 · Cited by 14
“Surprisingly, however, a recent analysis of AstraZeneca's drug development pipeline revealed that, among the projects classified as efficacy failures in Phase II, 40% were associated with a fundamental failure to link the supposed molecular target to the intended indication (Cook et al., 2014).”
Drug discovery in focal and segmental glomerulosclerosis
Pullen, N., & Fornoni, A. (2016) · Kidney International · doi:10.1016/j.kint.2015.12.058 · Cited by 14
Hummel, M., & Whiteside, G. T. (2016) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2016.08.007 · Cited by 17
Higgins, M. A., Marcin, L. R., Zusi, F. C., Gentles, R. G., Ding, M., Pearce, B. C., Easton, A. E., Kostich, W. A., Seager, M. A., Bourin, C., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.11.018 · Cited by 14
Quantitation of ERK1/2 inhibitor cellular target occupancies with a reversible slow off-rate probe
Lebraud, H., Surova, O. V., Courtin, A., O’Reilly, M., Valenzano, C. R., Nordlund, P., & Heightman, T. D. (2018) · Chemical Science · doi:10.1039/c8sc02754d · Cited by 15
Human Cell-Based in vitro Phenotypic Profiling for Drug Safety-Related Attrition
Berg, E. L. (2019) · Frontiers in Big Data · doi:10.3389/fdata.2019.00047 · Cited by 14
Cross-laboratory analytical validation of the cardiac biomarker NT-proANP in rat
Vinken, P., Reagan, W. J., Rodriguez, L.-A., Buck, W. R., Lai‐Zhang, J., Goeminne, N., Barbacci, G., Liu, R., King, N. M. P., Engle, S. K., et al. (2015) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2015.10.002 · Cited by 14
Animal disease models for drug screening: the elephant in the room?
Tsukamoto, T. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.02.012 · Cited by 14
Drug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
Digitalization of toxicology: improving preclinical to clinical translation
Berridge, B. R., Baran, S. W., Kumar, V., Bratcher-Petersen, N., Ellis, M., Liu, C., & Robertson, T. L. (2024) · Frontiers in Toxicology · doi:10.3389/ftox.2024.1377542 · Cited by 15
Mechanical signatures and models of the bone marrow niche
Rogkoti, T., Donnelly, H., Dalby, M. J., & Salmerón‐Sánchez, M. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00305-6 · Cited by 16
Cancer nanomedicine: Concepts, promises, and challenges
Zhu, C., Preis, E., Bakowsky, U., & Xia, Y. (2025) · Chem · doi:10.1016/j.chempr.2025.102706 · Cited by 17
Cellular Target Deconvolution of Small Molecules Using a Selection-Based Genetic Screening Platform
Zhao, J., Tang, Z., Selvaraju, M., Johnson, K. A., Douglas, J. T., Gao, P. F., Petrassi, H. M., Wang, M. Z., & Wang, J. (2022) · ACS Central Science · doi:10.1021/acscentsci.2c00609 · Cited by 13
The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging
Owen, M., Bose, N., Nisenbaum, L., Partrick, K. A., & Fillit, H. M. (2023) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2023.111 · Cited by 16
“Clinical trials using biomarkers have a greater success rate than those that do not (10), particularly when used strategically in multiple COUs (11, 12).”
BackgroundAnalyzing the functional effects of DNA variants with gene editing
Cooper, S., Obolenski, S., Waters, A. J., Bassett, A. R., & Coelho, M. A. (2024) · Cell Reports Methods · doi:10.1016/j.crmeth.2024.100776 · Cited by 19
Arakawa, H., Higuchi, D., Takahashi, E., Matsushita, K., Nedachi, S., Peng, H., Kadoguchi, M., Morimura, K., Araki, A., Kondo, M., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.08.009 · Cited by 13
Information Disclosure and Competitive Dynamics: Evidence from the Pharmaceutical Industry
Kao, J. L. (2024) · Management Science · doi:10.1287/mnsc.2022.01161 · Cited by 19
Daurio, N. A., Wang, S.-P., Chen, Y., Zhou, H., McLaren, D. G., Roddy, T. P., Johns, D. G., Milot, D. P., Kasumov, T., Erion, M. D., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.241091 · Cited by 13
“Because a lack of efficacy in patients remains a key reason why drug candidates fail (Arrowsmith and Miller, 2013; Plenge et al., 2013; Cook et al., 2014), it seems important to cross-reference a parts list (i.e., an expression profile) with an instruction manual (i.e., an integrative study of…”
BackgroundMethodHigh-throughput Measurement of Gut Transit Time Using Larval Zebrafish
Cassar, S. C., Huang, X., & Cole, T. B. (2018) · Journal of Visualized Experiments · doi:10.3791/58497 · Cited by 13
Déglin, S. E., Chen, C. L., Miller, D. J., Lewis, R. J., Chang, E. T., Hamade, A. K., & Erickson, H. S. (2021) · Global Epidemiology · doi:10.1016/j.gloepi.2021.100048 · Cited by 14
Pruimboom‐Brees, I., Gupta, S., Chemuturi, N. V., Booler, H. S., Nimz, E. L., Ramos, M. F., Caruso, A., Maass, K. F., Bantseev, V., Huang, Q., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13480 · Cited by 14
Unlocking proteomic heterogeneity in complex diseases through visual analytics
Bhavnani, S. K., Dang, B., Bellala, G., Divekar, R. D., Visweswaran, S., Brasier, A. R., & Kurosky, A. (2015) · PROTEOMICS · doi:10.1002/pmic.201400451 · Cited by 12
“Given the growing realization that both target and patient selection play a critical role in the success of clinical trials [61], we believe that subject-protein networks could be used to identify subgroups of patients (e.g. those with and without activation of the IL-5 signaling pathway) as…”
Benchmarking of Human Dose Prediction for Inhaled Medicines from Preclinical In Vivo Data
Ericsson, T., Fridén, M., Mårdh, C. K., Dainty, I. A., & Grime, K. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2218-z · Cited by 13
Collaboration and competition: ethics in toxicology
Walker, E. S., & Roberts, R. A. (2018) · Toxicology Research · doi:10.1039/c7tx00306d · Cited by 13
Predictive in vitro toxicology screening to guide chemical design in drug discovery
Johansson, J., Larsson, M. H., & Hornberg, J. J. (2019) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2019.08.005 · Cited by 12
In Vitro and In Vivo Tumor Models for the Evaluation of Anticancer Nanoparticles
Abreu, T. R., Biscaia-Caleiras, M., Gonçalves, N., Fonseca, N. A., & Moreira, J. N. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-58174-9_12 · Cited by 18
Applications of artificial intelligence in drug discovery for neurological diseases
Ekins, S., & Lane, T. R. (2025) · Neurotherapeutics · doi:10.1016/j.neurot.2025.e00624 · Cited by 14
“Critically, toxicity is one of the most important reasons for the failure of most clinical studies, with CNS toxicity linked to a 30 % clinical trial failure rate [14].”
Lanz, T. A., Ruprecht, K., Somps, C. J., Göpfert, J. C., Kam-Thong, T., Tekle, F. B., Fader, K. A., Yañez, V. A. C., Meyer, V., Friedrich, S., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13246-2 · Cited by 14
“Upwards of 14% of new drug candidates were discontinued in preclinical development due to neurotoxicity in a representative pharmaceutical company survey [15, 39].”
Mouse organoids as an in vitro tool to study the in vivo intestinal response to cytotoxicants
Jardí, F., Kelly, C., Teague, C. R., Fowler-Williams, H., Sévin, D. C., Rodrigues, D., Jo, H., Ferreira, S., Herpers, B., van Heerden, M., et al. (2022) · Archives of Toxicology · doi:10.1007/s00204-022-03374-3 · Cited by 15
“Drug-induced GI toxicity significantly contributes to project discontinuation during drug development (Cook et al. 2014).”
BackgroundPark, M., Kim, D., Kim, I., Im, S., & Kim, S. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104705 · Cited by 12
“4 Thus, previous studies have explored the relationship be-tween the side effects of drugs and the characteristics of drug targets, including the centrality of the protein interaction network 5 – 7 and gene expression pro fi les across tissues.”
BackgroundMatsushita, K., Toyoda, T., Akane, H., Morikawa, T., & Ogawa, K. (2023) · Journal of Toxicologic Pathology · doi:10.1293/tox.2023-0111 · Cited by 12
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk
Kronzer, V. L., Sparks, J. A., Raychaudhuri, S., & Cerhan, J. R. (2024) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01096-7 · Cited by 15
Sun, D., Macedonia, C. R., Chen, Z., Chandrasekaran, S., Najarian, K., Zhou, S. Y., Cernak, T., Ellingrod, V. L., Jagadish, H. V., Marini, B. L., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01684 · Cited by 15
Wijaya, L. S., Kunnen, S. J., Trairatphisan, P., Fisher, C., Crosby, M. E., Schaefer, K., Bodié, K., Vaughan, E. E., Breidenbach, L., Reich, T., et al. (2025) · Cell Biology and Toxicology · doi:10.1007/s10565-025-10003-z · Cited by 15
“Drug-induced kidney injury (DIKI) remains a major problem for drug development and clinical safety management due to poor understanding of the underlying mechanisms (Cook et al. 2014; Pavkovic et al. 2014).”
Genetic susceptibility to rheumatoid arthritis and its implications for novel drug discovery
Yarwood, A., Eyre, S., & Worthington, J. (2016) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2016.1195366 · Cited by 14
“to only 43% without genetic support [5].”
From the Data on Many, Precision Medicine for “One”: The Case for Widespread Genomic Data Sharing
Scollen, S., Page, A. J. H., Wilson, J., & on behalf of the Global Alliance for Genomics and Health (2017) · Biomedicine Hub · doi:10.1159/000481682 · Cited by 12
Chaves, N. L., Amorim, D. A., Lopes, C. A. P., Estrela‐Lopis, I., Böttner, J., de Souza, A. R., & Báo, S. N. (2019) · Cancer Nanotechnology · doi:10.1186/s12645-019-0052-1 · Cited by 12
The Opportunities and Use of Imaging to Measure Target Engagement
Maynard, J., & Hart, P. J. (2019) · SLAS DISCOVERY · doi:10.1177/2472555219897270 · Cited by 13
Whiteaker, J. R., Wang, T., Zhao, L., Schoenherr, R. M., Kennedy, J. J., Voytovich, U. J., Ivey, R. G., Huang, D., Lin, C., Colantonio, S., et al. (2021) · Cancers · doi:10.3390/cancers13153843 · Cited by 15
“Indeed, AstraZeneca recently revised its drug development framework [12,13] with a view to increasing success rates of drugs in pivotal Phase 3 studies.”
BackgroundWright, M. R. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1787-8_21 · Cited by 13
Improving Translational Paradigms in Drug Discovery and Development
Williams, M. J. (2021) · Current Protocols · doi:10.1002/cpz1.273 · Cited by 12
“Cook et al. (2014) cite one project that had seven backup compounds considered to be successful candidates, all of which failed due to the same preclinical toxicity issue.”
BackgroundResultInfluentialDas, S., Taylor, K., Beaulah, S. A., & Gardner, S. (2022) · Patterns · doi:10.1016/j.patter.2022.100496 · Cited by 18
“29 However, although GWASs have revealed several disease-associated genes, their translation into the clinic has been far from successful, especially in complex, chronic diseases.”
BackgroundThe Pursuit of Enzyme Activation: A Snapshot of the Gold Rush
Teng, M., Young, D. W., & Tan, Z. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01291 · Cited by 12
Inflammation across tissues: can shared cell biology help design smarter trials?
Hosack, T., Thomas, T. R., Ravindran, R. P., Uhlig, H. H., Travis, S. P. L., & Buckley, C. D. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01007-2 · Cited by 14
“Moreover, finding the right target paired with the right tissue is acknowledged as an indicator of programme success 42 .”
BackgroundOligonucleotide Therapies for the Lung: Ready to Return to the Clinic?
Kumar, M., & Moschos, S. A. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.002 · Cited by 12
Opportunities and pitfalls in clinical proof-of-concept: principles and examples
Chen, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.045 · Cited by 12
Obajdin, J., Cotter, M., Snelling, S., Dremier, S., Ron, P. D., Fleurance, R., Valentin, J., da Costa, A. N., & Gryshkova, V. (2018) · Toxicological Sciences · doi:10.1093/toxsci/kfy204 · Cited by 12
Meier-Hubberten, J. C., & Sanderson, M. P. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9145-7_11 · Cited by 14
Medicines discovery for auditory disorders: Challenges for industry
Cousins, R. P. C. (2019) · The Journal of the Acoustical Society of America · doi:10.1121/1.5132706 · Cited by 12
Mathematical modeling of efficacy and safety for anticancer drugs clinical development
Lavezzi, S. M., Borella, E., Carrara, L., Nicolao, G. D., Magni, P., & Poggesi, I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2018.1388369 · Cited by 12
“Mathematical modeling provides a means to reduce attrition, gathering and leveraging the information gained throughout all the investigational studies about the mechanism of action and the safety and tolerability profile of a potential drug [5,10].”
BackgroundThe great debate: Should Osteoarthritis Research Focus on “Mice” or “Men”?
Hunter, D. J., & Little, C. B. (2015) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2015.07.029 · Cited by 13
Mendelian randomization: a premature burial?Preprint
Smith, G. D. (2015) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/021386 · Cited by 12
A Review of the Pharmaceutical R&D Efficiency: Costs, Timelines, and Probabilities
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016) · Wiley eBooks · doi:10.1002/9783527693405.ch4 · Cited by 12
PET Imaging in Drug Discovery and Development
Donnelly, D. J. (2020) · Wiley eBooks · doi:10.1002/9781119500575.ch22 · Cited by 19
Stebbeds, W., Raniga, K., Standing, D., Wallace, I., Bayliss, J., Brown, A. J., Kasprowicz, R., Dalmas, D. A., Deakyne, J. S., Clements, P., et al. (2023) · Toxicological Sciences · doi:10.1093/toxsci/kfad065 · Cited by 11
Yang, K., Kong, R., Spiegel, R. J., Baird, J. D., O’Keefe, K., Howell, B. A., & Watkins, P. B. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3136 · Cited by 11
“13,14 These “missed” clinical hepatotoxicity signals are attributed to species differences in drug metabolism, formation, and quenching of reactive metabolites, or physiological processes relevant to toxicity mechanisms.”
BackgroundSandelius, Å., Naseer, H., Lindqvist, J., Wilson, A., & Henderson, N. (2024) · Bioanalysis · doi:10.1080/17576180.2024.2360361 · Cited by 15
Sakolish, C., Tsai, H.-H. D., Lin, H.-C., Bajaj, P., Villenave, R., Ferguson, S. S., Stanko, J. P., Becker, R. A., Hewitt, P., Chiu, W. A., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13030563 · Cited by 11
“Kidney toxicity contributes to approximately 9% of drug termination in the clinical phase [8] and is often identified late in drug development due to the inadequate sensitivity of preclinical models and the limitations of the human blood and urine biomarkers of nephrotoxicity [9–11].”
Microphysiological Systems: A Pathologist’s Perspective
Sura, R., Vleet, T. V., & Berridge, B. R. (2020) · Veterinary Pathology · doi:10.1177/0300985820908794 · Cited by 12
“6 billion per molecule(29,30) and takes 12 to 15 years.(23) Failure of drugs during clinical trials is largely due to toxicity or lack of clinical efficacy.”
BackgroundKaczmarczyk, J. A., Roberts, R. R., Luke, B. T., Chan, K. C., Wagoner, C. M. V., Felder, R. A., Saul, R. G., Colantonio, S., & Blonder, J. (2021) · Oncotarget · doi:10.18632/oncotarget.28072 · Cited by 12
“[2] Despite extensive research and economic investments, about 95% of new drugs against lung carcinoma eventually fail in clinical trials.[3, 4] While there are many hypotheses and explanations for this poor clinical translation rate, it is well accepted that conventionally used preclinical in vitro testing models (e.”
BackgroundMohr, M., Chambard, J., Ballet, V., & Schmidt, F. (2022) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2022.107172 · Cited by 12
Winter, M. J., Ono, Y., Ball, J. S., Walentinsson, A., Michaëlsson, E., Tochwin, A., Scholpp, S., Tyler, C. R., Rees, S., Hetheridge, M. J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827686 · Cited by 11
“Crucially, it is recognised that the demonstration of genetic linkage to a disease phenotype provides more confidence in target validation and a lower likelihood of drug failure due to a lack of efficacy (Cook et al., 2014).”
Background
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.